Shares of KB Home dropped 4% as the homebuilder reversed course from gains on Friday. The company's fiscal first-quarter financial report came out late Thursday, and it included a revenue increase of ...
Monday was one of the strongest days in stock market history as investors responded positively to the idea that the U.S. would be willing to talk to China about their trade differences. The Dow was up ...
Protagonist Therapeutics' stock has experienced significant volatility over the past three years, with multiple setbacks and recoveries. The company's lead drug candidate, Rusfertide, indicated for ...
The ICONIC program now includes four Phase 3 studies evaluating JNJ-2113; Co-primary endpoints for all four studies are PASI-90 and/or IGA 0 or 1 Protagonist eligible to receive $115 million milestone ...
IL-23 receptor antagonist icotrokinra hit co-primary phase III endpoints in moderate to severe plaque psoriasis, positioning the oral peptide at the forefront of a multibillion-dollar franchise for ...
Shares of KB Home dropped 4% as the homebuilder reversed course from gains on Friday. The company's fiscal first-quarter financial report came out late Thursday, and it included a revenue increase of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback